Editing Necrotizing fasciitis (section)

===Add-on therapy===
* '''[[Hyperbaric oxygen]] (HBO)''': In theory, HBO decreases local inflammation in the wound and bolsters the body's immune response. However, the impact of HBO in patients with NSTIs remains unclear.<ref name=Hu2018/>
* '''[[Intravenous immunoglobulin]] (IVIG)''': IVIG is intended to combat the exotoxins released by ''[[Streptococcus pyogenes|S. pyogenes]]'' [[toxic shock syndrome]] (TSS).<ref name=":4">{{Citation |last1=Evans |first1=Heather Leigh |title=Management of Necrotizing Soft Tissue Infection |date=2020 |work=Evidence-Based Critical Care: A Case Study Approach |pages=697–701 |editor-last=Hyzy |editor-first=Robert C. |url=https://link.springer.com/chapter/10.1007/978-3-030-26710-0_93 |access-date=2024-12-05 |place=Cham |publisher=Springer International Publishing |language=en |doi=10.1007/978-3-030-26710-0_93 |isbn=978-3-030-26710-0 |last2=Napolitano |first2=Lena M. |last3=Bulger |first3=Eileen M. |editor2-last=McSparron |editor2-first=Jakob|url-access=subscription }}</ref>  However, studies have failed to find any effect on patient mortality.<ref name=":4" /> There may also be serious adverse effects with IVIG use.<ref name=Hu2018/>
* '''AB103''': Reltecimod aka AB103 is a new drug that binds to the CD28 T-cell receptor and thus mitigates the effects of bacterial toxins. Studies show that it may decrease the severity of organ failure in NF patients.<ref name=":4" /> However, other studies found no difference in mortality with this therapy.<ref name=Hu2018/>
* '''Supportive therapy''': Intravenous hydration, wound care, anticoagulants to prevent thromboembolic events, pain control, vasopressors, etc. should always be provided to patients when appropriate.<ref name=":5" />